TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05609097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRIME
Description: PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.

Intervention type: OTHER
Group type: OTHER
Intervention: COMBO
Description: COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMBO
Description: COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range.
Study: NCT05163912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual home intervention
Description: Group classes with active videogames and discussions
Study: NCT06572501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
Description: This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
Description: This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
Study: NCT06572696

Intervention type: DIAGNOSTIC_TEST
Intervention: Shulder Ultrasound
Description: Ultrasound Shoulder Pathology Rating Scale (USPRS) will be used in the evaluation. While the participants are in a sitting position; A total of 5 variables, including bicipital tendinopathy, supraspinatus tendinopathy, greater tuberculum cortical surface irregularity, supraspinatus dynamic and subscapularis dynamic examination, are evaluated and scored according to the level of pathology; The total USPRS score is obtained by adding the scores of all variables.~Another parameter evaluated by ultrasonography in this study is the acromiohumeral distance measurement. In AH distance measurement with MSK-US, two measurements will be made with all participants in a neutral resting position and their hands at the top of the circle with the elbow angle of 110 °. In both positions, the probe will be placed longitudinally at the lateral point of the acromion determined by palpation, the distance determined between the acromion and the humeral head will be displayed and measured.
Study: NCT04184882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral
Study: NCT06573541

Intervention type: DEVICE
Intervention: Use of ultrasound
Description: Use of ultrasound in the initial management of patients in shock
Study: NCT04184882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bocidelpar
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT04434209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subject management guided by NephroCheck® test
Description: NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care patient management
Study: NCT05171920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auxora
Description: All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
Study: NCT06534320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-302168S
Description: SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 6 subjects receive DA-302168S tablets.
Study: NCT06538779

Intervention type: DIAGNOSTIC_TEST
Intervention: elastography,usg
Description: Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.

Intervention type: DIAGNOSTIC_TEST
Intervention: elastography,usg
Description: Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
Study: NCT06085105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPIPE Training
Description: A two day training covering the following topics: understanding stress \& burnout and developing positive coping mechanisms, bias awareness \& mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support groups
Description: Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
Study: NCT05145647

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Add-on Brachytherapy
Description: Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment if applicable will be finished within 2 weeks after the first one, a total of 5-10Gy in 1-2 fractions will be delivered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRAXX Esophageal Brachytherapy Applicator
Description: The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
Study: NCT06085105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership engagement
Description: Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embedded champions
Description: To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
Study: NCT05859126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maternal Choline Supplementation 930 mg/d
Description: Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maternal Choline Supplementation 480 mg/d
Description: Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
Study: NCT05910320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Vital Signs Monitoring Device
Description: The prototype will be used to non-invasively measure vital signs. This prototype (preliminary version) is composed of a sensor module, a rechargeable battery, and electrodes. The device is housed in a waterproof, silicone casing.
Study: NCT05234398

Intervention type: BIOLOGICAL
Intervention: Blood and saliva samplings
Description: At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.

Intervention type: BIOLOGICAL
Intervention: Blood and saliva samplings
Description: At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
Study: NCT06568809

Intervention type: OTHER
Intervention: Time interval between recovery of body temperature and operation
Description: The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories: 0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks; And ≥ 3 months (control group).
Study: NCT05155735

Intervention type: PROCEDURE
Intervention: Replantation
Description: Surgical reattachment of a severed body part

Intervention type: PROCEDURE
Intervention: Primary wound closure
Description: Primary wound closure with removal of exposed bone
Study: NCT04777461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey on patient's perspectives on the development of an structured education programme for PCOS
Description: The outcome of this survey will help with developing curriculum for the structured education programme.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-pilot questionnaire
Description: The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piloting the structured education programme for PCOS
Description: Piloting the education program through 2 educational group sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-pilot questionnaire
Description: The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive outcomes outcome evaluation form
Description: This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
Study: NCT06542224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain stimulation
Description: All subjects will receive bilateral surgical implantation of DBS system.
Study: NCT04439097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise program associated with a Mediterranean diet
Description: In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
Study: NCT06534320

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DA-302168S
Description: SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 2 subjects receive placebo of DA-302168S tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-302168S
Description: MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 8 subjects receive study DA-302168S tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DA-302168S
Description: MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive study placebo of DA-302168S tablets.
Study: NCT05319418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Blood Pressure Monitoring
Description: Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
Study: NCT06423937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
Description: Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2） Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
Description: Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2） Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle
Study: NCT05372198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chohort 1: Surufatinib
Description: Surufatinib 300mg, qd, every 3 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chohort 2: Immunotherapy
Description: Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chohort 2: Surufatinib
Description: Surufatinib 250mg, qd, every 3 weeks as a cycle
Study: NCT06460194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botuinum toxin
Description: Injection of botulinum toxin in the palm of the hand
Study: NCT06020911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: 17 primary second molars of 17 children will be capped with Biodentine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theracal light cured
Description: 17 primary second molars of 17 children will be capped with Theracal light cured
Study: NCT06460194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botuinum toxin
Description: Injection of botulinum toxin in the palm of the hand
Study: NCT05211219

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AOÇ Kefir
Description: AOÇ Kefir

Intervention type: OTHER
Group type: OTHER
Intervention: Food without additional food supplements
Description: Food without additional food supplements
Study: NCT05540223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DREAMS 3G RMS
Description: Subject undergoes implantation of DREAMS 3G RMS
Study: NCT05015803

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CBTi with Application
Description: Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
Study: NCT05540223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience DES
Description: Subject undergoes implantation of Xience DES
Study: NCT05668494

Intervention type: OTHER
Group type: OTHER
Intervention: immediate loading of implants
Description: This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
Study: NCT05015803

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTi
Description: Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
Study: NCT04952766

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples
Description: Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)
Study: NCT05015803

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
Study: NCT06385873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
Study: NCT04682808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-338
Description: FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.